Drug Trial Radar · NCT02435095
Antipsychotic Induced Structural and Functional Brain Changes
Last checked: Nov 20, 2026Latest source record: Nov 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
174
Actual
Start
May 2015
Primary completion
Aug 2020
Study completion Aug 2020
Sponsor
- Lead sponsor
- RWTH Aachen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 6, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Continuation of antipsychotic drug treatment for at least 12 months after remission of the first psychotic episode represents the gold clinical standard, and it is recommended by all international treatment guidelines. Numerous studies have shown that the risk of relapse is significantly increased, if drug treatment is terminated prematurely. However, only a minority of patients achieve functional remission, even if they fully comply with treatment. Long-term adverse effects of the currently available drugs, specifically brain grey matter loss and development of supersensitivity psychosis, might outweigh their benefits. Thus, the current standard of long-term maintenance antipsychotic treatment, which has the primary goal of relapse prevention, has to be questioned. Here the investigators hypothesize that intermittent treatment (experimental) with antipsychotics, which is directed exclusively against the positive symptoms of Schizophrenia, is associated with less loss in total grey matter volume than maintenance treatment (control). Furthermore, the investigators hypothesise that this targeted treatment approach is associated with better functional outcome (fewer negative symptoms, better cognitive performance, better quality of life) than continuous antipsychotic treatment,although the latter is initially associated with fewer relapses.The aim of the present study is to compare two different drug therapies -maintenance therapy versus on-demand, intermittent therapy- in terms of their treatment's success and the structural changes in the brain.
Conditions
- Schizophrenia
Interventions
Maintenance treatmentDrug
Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months. All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Intermittent treatmentDrug
Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms. All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total grey matter volumeTime frame: over 12 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Alexianer Aachen GmbH
Aachen, Germany
Zentrum für Neurologie und Seelische Gesundheit im Kapuziner Karree Aachen
Aachen, Germany
LVR Klinik Bonn
Bonn, Germany
LVR Klinik Düren
Düren, Germany
Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf
Düsseldorf, Germany
LVR Klinik Essen
Essen, Germany
ViaNobis Gangelt
Gangelt, Germany
Klinik Königshof (Abteilung für Allgemeine Psychiatrie)
Krefeld, Germany
LVR Klinik Langenfeld
Langenfeld, Germany
LVR Klinik Viersen
Viersen, Germany
RWTH University Hospital Aachen
Aachen, North Rhine-Westphalia, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.